313 related articles for article (PubMed ID: 11504907)
1. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice.
Podsypanina K; Lee RT; Politis C; Hennessy I; Crane A; Puc J; Neshat M; Wang H; Yang L; Gibbons J; Frost P; Dreisbach V; Blenis J; Gaciong Z; Fisher P; Sawyers C; Hedrick-Ellenson L; Parsons R
Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10320-5. PubMed ID: 11504907
[TBL] [Abstract][Full Text] [Related]
2. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.
Neshat MS; Mellinghoff IK; Tran C; Stiles B; Thomas G; Petersen R; Frost P; Gibbons JJ; Wu H; Sawyers CL
Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10314-9. PubMed ID: 11504908
[TBL] [Abstract][Full Text] [Related]
3. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma.
Pene F; Claessens YE; Muller O; Viguié F; Mayeux P; Dreyfus F; Lacombe C; Bouscary D
Oncogene; 2002 Sep; 21(43):6587-97. PubMed ID: 12242656
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells.
Grünwald V; DeGraffenried L; Russel D; Friedrichs WE; Ray RB; Hidalgo M
Cancer Res; 2002 Nov; 62(21):6141-5. PubMed ID: 12414639
[TBL] [Abstract][Full Text] [Related]
5. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.
Shi Y; Gera J; Hu L; Hsu JH; Bookstein R; Li W; Lichtenstein A
Cancer Res; 2002 Sep; 62(17):5027-34. PubMed ID: 12208757
[TBL] [Abstract][Full Text] [Related]
6. The biology and clinical relevance of the PTEN tumor suppressor pathway.
Sansal I; Sellers WR
J Clin Oncol; 2004 Jul; 22(14):2954-63. PubMed ID: 15254063
[TBL] [Abstract][Full Text] [Related]
7. mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo.
Kwon CH; Zhu X; Zhang J; Baker SJ
Proc Natl Acad Sci U S A; 2003 Oct; 100(22):12923-8. PubMed ID: 14534328
[TBL] [Abstract][Full Text] [Related]
8. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
Han S; Khuri FR; Roman J
Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245
[TBL] [Abstract][Full Text] [Related]
9. PI3K/Akt/mTOR signaling & its regulator tumour suppressor genes
Makker A; Goel MM; Mahdi AA; Bhatia V; Das V; Agarwal A; Pandey A
Indian J Med Res; 2016 May; 143(Supplement):S112-S119. PubMed ID: 27748285
[TBL] [Abstract][Full Text] [Related]
10. Constitutive cellular expression of PI 3-kinase is distinct from transient expression.
Auger KR; Wang J; Narsimhan RP; Holcombe T; Roberts TM
Biochem Biophys Res Commun; 2000 Jun; 272(3):822-9. PubMed ID: 10860837
[TBL] [Abstract][Full Text] [Related]
11. Roles of phosphatidylinositol 3'-kinase and mammalian target of rapamycin/p70 ribosomal protein S6 kinase in K-Ras-mediated transformation of intestinal epithelial cells.
Shao J; Evers BM; Sheng H
Cancer Res; 2004 Jan; 64(1):229-35. PubMed ID: 14729629
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of insulin signaling and adipogenesis by rapamycin: effect on phosphorylation of p70 S6 kinase vs eIF4E-BP1.
El-Chaâr D; Gagnon A; Sorisky A
Int J Obes Relat Metab Disord; 2004 Feb; 28(2):191-8. PubMed ID: 14970836
[TBL] [Abstract][Full Text] [Related]
13. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts.
Wu L; Birle DC; Tannock IF
Cancer Res; 2005 Apr; 65(7):2825-31. PubMed ID: 15805283
[TBL] [Abstract][Full Text] [Related]
14. mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma.
Hu X; Pandolfi PP; Li Y; Koutcher JA; Rosenblum M; Holland EC
Neoplasia; 2005 Apr; 7(4):356-68. PubMed ID: 15967113
[TBL] [Abstract][Full Text] [Related]
15. Insulin-induced Drosophila S6 kinase activation requires phosphoinositide 3-kinase and protein kinase B.
Lizcano JM; Alrubaie S; Kieloch A; Deak M; Leevers SJ; Alessi DR
Biochem J; 2003 Sep; 374(Pt 2):297-306. PubMed ID: 12841848
[TBL] [Abstract][Full Text] [Related]
16. A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1.
Ozes ON; Akca H; Mayo LD; Gustin JA; Maehama T; Dixon JE; Donner DB
Proc Natl Acad Sci U S A; 2001 Apr; 98(8):4640-5. PubMed ID: 11287630
[TBL] [Abstract][Full Text] [Related]
17. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies.
Panwalkar A; Verstovsek S; Giles FJ
Cancer; 2004 Feb; 100(4):657-66. PubMed ID: 14770419
[TBL] [Abstract][Full Text] [Related]
18. Activation of phosphatidylinositol 3-kinase, protein kinase B, and p70 S6 kinases in lipopolysaccharide-stimulated Raw 264.7 cells: differential effects of rapamycin, Ly294002, and wortmannin on nitric oxide production.
Salh B; Wagey R; Marotta A; Tao JS; Pelech S
J Immunol; 1998 Dec; 161(12):6947-54. PubMed ID: 9862729
[TBL] [Abstract][Full Text] [Related]
19. Restraining PI3K: mTOR signalling goes back to the membrane.
Harrington LS; Findlay GM; Lamb RF
Trends Biochem Sci; 2005 Jan; 30(1):35-42. PubMed ID: 15653324
[TBL] [Abstract][Full Text] [Related]
20. IL2-dependent phosphorylation of 40S ribosomal protein S6 is controlled by PI-3K/mTOR signalling in CTLL2 cells.
Tuhácková Z; Sloncová E; Vojtechová M; Sovová V
Int J Mol Med; 2004 Apr; 13(4):601-5. PubMed ID: 15010863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
